Trial Radar IA | ||
|---|---|---|
Lo studio clinico NCT02444741 per Neoplasia Solida Maligna, Carcinoma Polmonare Non a Piccole Cellule Metastatico, Cancro del Polmone Non a Piccole Cellule Stadio IV AJCC v7 è attivo, non in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui. | ||
Centro medico MD AndersonPembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Fase I, Fase II 126 Immunoterapia Randomizzato
I. To evaluate the safety and toxicity profile of intravenous MK-3475 (pembrolizumab) administered in combination with stereotactic body radiation therapy (SBRT) targeting 1-4 liver or thoracic lesion(s) in patients with metastatic non-small cell lung cancer (NSCLC). (Phase I) II. To evaluate the safety and toxicity profile of intravenous MK-3475 administered in combination with non-stereotactic ...
Mostra di piùPhase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC
- 2014-1020
- NCI-2015-01505 (Identificativo del registro) (CTRP (Clinical Trial Reporting Program))
- 2014-1020 (Altro identificativo) (M D Anderson Cancer Center)
Fase II
| Gruppo/Braccio di partecipanti | Intervento/Trattamento |
|---|---|
SperimentaleGroup I, Phase I (pembrolizumab + SBRT) Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity. | Radioterapia conformazionale tridimensionale Undergo 3D-CRT Radioterapia a modulazione d'intensità Undergo IMRT Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Terapia con radiazioni a fasci di protoni Undergo PBRT Radioterapia corporea stereotassica Undergo SBRT |
SperimentaleGroup I, Phase II (pembrolizumab + SBRT) Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity. | Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Radioterapia corporea stereotassica Undergo SBRT |
SperimentaleGroup II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT) Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration. | Radioterapia conformazionale tridimensionale Undergo 3D-CRT Radioterapia a modulazione d'intensità Undergo IMRT Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Terapia con radiazioni a fasci di protoni Undergo PBRT |
SperimentaleGroup II, Phase II (pembrolizumab + XRT upon PD) Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will ...Mostra di più | Radioterapia conformazionale tridimensionale Undergo 3D-CRT Radioterapia a modulazione d'intensità Undergo IMRT Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Terapia con radiazioni a fasci di protoni Undergo PBRT Radioterapia corporea stereotassica Undergo SBRT |
SperimentaleGroup III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT) Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61. | Radioterapia a modulazione d'intensità Undergo IMRT Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Terapia con radiazioni a fasci di protoni Undergo PBRT |
SperimentaleGroup IV, Phase II (pembrolizumab + XRT upon PD) Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will c...Mostra di più | Radioterapia conformazionale tridimensionale Undergo 3D-CRT Radioterapia a modulazione d'intensità Undergo IMRT Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Terapia con radiazioni a fasci di protoni Undergo PBRT |
SperimentaleGroup V, Phase II (low dose radiation therapy) Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47. | Radioterapia conformazionale tridimensionale Undergo 3D-CRT Radioterapia a modulazione d'intensità Undergo IMRT Analisi dei biomarcatori di laboratorio Correlative studies Pembrolizumab Given IV Terapia con radiazioni a fasci di protoni Undergo PBRT Terapia radiante Undergo low dose radiation therapy Radioterapia corporea stereotassica Undergo SBRT |
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Disease response, according to immune related response criteria (Phase I/II) | Treatment success will be defined as radiographic complete response or partial response measured using Pearson chi-squared or Fisher exact tests. | Beginning 3 months after initiation of treatment |
Incidence of toxicity (Phase I/II) | Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. | Up to 90 days after completion of treatment |
Maximum tolerated dose of pembrolizumab and stereotactic body radiation therapy (Phase I) | Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. | 22 days |
Maximum tolerated dose of pembrolizumab and non-stereotactic wide-field radiation therapy (Phase I) | Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. | 22 days |
Objective response (complete response + partial response) of the non-irradiated disease sites, according to Out-Field immune related response criteria (Phase II) | Assesed according to Out-Field immune related response criteria. Treatment success will be defined as radiographic complete response or partial response measured using Pearson chi-squared or Fisher exact tests. | Up to 5 years |
| Misure di esito | Descrizione della misura | Arco temporale |
|---|---|---|
Progression-free survival (Phase II) | Analysis conducted using Kaplan-Meier method. At the discretion of the investigators, multivariate Cox regression will be done to adjust for (among other factors): number of metastatic disease sites, number of prior treatments, primary cancer histology, age, pre-treatment Karnofsky performance scale, and Royal Marsden score. | From the time of enrollment to first evidence of progressive disease, assessed at 3 months after treatment initiation |
Overall survival | Analysis conducted using Kaplan-Meier method, with comparisons regarding overall survival made via the log-rank test. At the discretion of the investigators, multivariate Cox regression will be done to adjust for (among other factors): number of metastatic disease sites, number of prior treatments, primary cancer histology, age, pre-treatment Karnofsky performance scale, and Royal Marsden score. | Receipt of the first pembrolizumab dose to death, assessed up to 5 years |
- Pathologically confirmed non-small lung cancer; for patients in group 5, any solid tumor histology to be included
- Stage IV metastatic disease (only during the phase II)
- At least one thoracic or liver lesion amenable to radiation, for group 5 we need one area that can safely receive SBRT or WFRT, not restricted to lung or liver sites
- At least one additional non-contiguous lesion to the irradiated lesion amenable to radiographic evaluation
- Be willing and able to provide written informed consent/assent for the trial
- Have measurable disease based on immune related response criteria (irRC) criteria
- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
- Absolute neutrophil count (ANC) >= 1,500 /mcL (performed within 28 days prior to study registration up to the first dose of study drug)
- Platelets >= 100,000 /mcL (performed within 28 days prior to study registration up to the first dose of study drug)
- Hemoglobin >= 9 g/dL or >= 5.6 mmol/L (performed within 28 days prior to study registration up to the first dose of study drug)
- Serum creatinine =< 1.5 X upper limit of normal (ULN) or measured or calculated creatinine clearance (glomerular filtration rate \[GFR\] can also be used in place of creatinine or calculated creatinine clearance \[CrCl\]) or >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (creatinine clearance should be calculated per institutional standard) (performed within 28 days prior to study registration up to the first dose of study drug)
- Serum total bilirubin =< 1.5 X ULN or direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN (performed within 28 days prior to study registration up to the first dose of study drug)
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =< 2.5 X ULN or =< 5 X ULN for subjects with liver metastases (performed within 28 days prior to study registration up to the first dose of study drug)
- International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial prothrombin time (PTT) is within therapeutic range of intended use of anticoagulants (performed within 28 days prior to study registration up to the first dose of study drug)
- Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (performed within 28 days prior to study registration up to the first dose of study drug)
- Patients with brain metastasis will be included as long as they are free of neurologic symptoms related to metastatic brain lesions and who do not require or receive systemic corticosteroid therapy in the 14 days prior to beginning MK-3475 therapy
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
- We will allow XRT prior to study entry to other sites, with no washout period, allowed prior to study entry as long as at least one measurable sites of disease is kept unirradiated
Is currently participating in or has participated in a study of an investigational agent (except glutamine) or using an investigational device within 4 weeks of the first dose of treatment or 5 half lives, whichever is shorter
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment; unless the steroid therapy is for physiological replacement
Has a diagnosis of active scleroderma, lupus, or other autoimmune disease which by the opinion of the treating radiation oncologist precludes safe radiation therapy
Has had prior radiation therapy to all available thoracic and liver lesions such that additional radiation therapy is unsafe by the opinion of the treating radiation oncologist
Has had a prior monoclonal antibody within 4 weeks or 5 half-lives, which ever is shorter, prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
- Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment
Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents; subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule; subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study; subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Has an active infection requiring systemic therapy or hospital admission
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
Has known active hepatitis B (e.g., hepatitis B virus HBsAg surface protein antigen \[HBsAg\] reactive) or hepatitis C (e.g., hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected)
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Symptomatic brain metastasis
Has experienced a dose limiting toxicity on treatment with either prior radiation or anti programmed cell death 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitor therapy
Centro medico MD AndersonTexas